Funds › Propel Bio Management, LLC
Propel Bio Management, LLC
13F for Q3 2026, filed Nov 13, 2026. 30 positions worth $188.6M.Managers with more than $100 million in US-listed stocks list their holdings each quarter, within 45 days of quarter end. Long positions only: no short sales or cash.
Ask your AI about this
Connect Claude, ChatGPT, Gemini or Grok (Microsoft 365 Copilot coming soon) to 13F.ai and ask in plain English. Copy a question to get started:
Using 13F.ai, what are the biggest new, added, trimmed and exited positions of Propel Bio Management, LLC in the latest 13F quarter?
Using 13F.ai, how has Propel Bio Management, LLC's portfolio concentration changed over the last four quarters?
Using 13F.ai, which of Propel Bio Management, LLC's top holdings have also been bought by insiders recently?
Connect your AI · Plans and the 7-day free trial (card required)
Holdings, Q3 2026
Largest first. Common shares only.
| # | The fund's own figures at the end of the quarter. A report can be up to 45 days old when it is filed. Options and bonds are not counted here. | Filing | ||||
|---|---|---|---|---|---|---|
| 1 | PAGP Plains GP Holdings, L.P. · Ltd Partnr Int A | 1.27M | $33.0M | 17.5% | Unchanged | 13F ↗ |
| 2 | ACHV Achieve Life Sciences, Inc. | 3.86M | $31.3M | 16.6% | -4.2% | 13F ↗ |
| 3 | DCTH Delcath Systems, Inc. | 604,664 | $9.7M | 5.1% | -30.6% | 13F ↗ |
| 4 | COLL Collegium Pharmaceutical, Inc. | 410,175 | $9.0M | 4.7% | New | 13F ↗ |
| 5 | CORT Corcept Therapeutics Incorporated | 75,274 | $8.7M | 4.6% | -44.9% | 13F ↗ |
| 6 | AQST Aquestive Therapeutics, Inc. | 278,723 | $8.6M | 4.6% | -80.7% | 13F ↗ |
| 7 | MIST Milestone Pharmaceuticals Inc. | 9.45M | $8.2M | 4.3% | +27.2% | 13F ↗ |
| 8 | PHAT Phathom Pharmaceuticals, Inc. | 1.11M | $8.1M | 4.3% | +5.3% | 13F ↗ |
| 9 | CMPS COMPASS Pathways Plc · ADR | 549,186 | $6.8M | 3.6% | -4.2% | 13F ↗ |
| 10 | OBIO Orchestra BioMed Holdings, Inc. | 896,701 | $5.6M | 3.0% | Unchanged | 13F ↗ |
| 11 | MAZE Maze Therapeutics, Inc. | 191,998 | $5.2M | 2.8% | +338% | 13F ↗ |
| 12 | ABEO Abeona Therapeutics Inc. | 956,007 | $5.0M | 2.7% | -2.8% | 13F ↗ |
| 13 | ARTV Artiva Biotherapeutics, Inc. | 696,436 | $5.0M | 2.6% | Unchanged | 13F ↗ |
| 14 | KYTX Kyverna Therapeutics, Inc. | 700,595 | $4.8M | 2.5% | -20.7% | 13F ↗ |
| 15 | IVA Inventiva S.A. · ADR | 1.13M | $4.2M | 2.2% | -11.5% | 13F ↗ |
| 16 | CABA Cabaletta Bio, Inc. | 2.05M | $3.9M | 2.1% | New | 13F ↗ |
| 17 | SABS SAB Biotherapeutics, Inc. | 1.19M | $3.8M | 2.0% | +10.3% | 13F ↗ |
| 18 | PROK ProKidney Corp. | 2.01M | $3.3M | 1.8% | New | 13F ↗ |
| 19 | CRVS Corvus Pharmaceuticals, Inc. | 264,310 | $3.0M | 1.6% | +276% | 13F ↗ |
| 20 | PALI Palisade Bio, Inc. | 2.22M | $3.0M | 1.6% | -13.9% | 13F ↗ |
| 21 | OCUL Ocular Therapeutix, Inc. | 357,966 | $2.7M | 1.5% | Unchanged | 13F ↗ |
| 22 | SCYX SCYNEXIS, Inc. | 541,474 | $2.7M | 1.4% | -0.4% | 13F ↗ |
| 23 | FDMT 4D Molecular Therapeutics, Inc. | 179,154 | $2.6M | 1.4% | -29.1% | 13F ↗ |
| 24 | OVID Ovid Therapeutics Inc. | 1.02M | $2.5M | 1.3% | -8.7% | 13F ↗ |
| 25 | IMUX Immunic, Inc. | 236,734 | $2.2M | 1.2% | -27.2% | 13F ↗ |
| 26 | UPB Upstream Bio, Inc. | 335,389 | $1.8M | 0.9% | -4.3% | 13F ↗ |
| 27 | IRD Opus Genetics, Inc. | 270,036 | $1.3M | 0.7% | New | 13F ↗ |
| 28 | CLDX Celldex Therapeutics, Inc. | 37,539 | $1.2M | 0.6% | -63.8% | 13F ↗ |
| 29 | SGP SpyGlass Pharma, Inc. | 41,418 | $1.1M | 0.6% | New | 13F ↗ |
| 30 | LONA LeonaBio, Inc. | 149,279 | $532.9K | 0.3% | Unchanged | 13F ↗ |
Changes since Q2 2026
5 new, 5 added to, 15 trimmed, 4 exited, 5 unchanged. By estimated dollars.
New positions (5)
Added to (5)
Trimmed (15)
| AQST Aquestive Therapeutics, Inc. | 278,723 | -80.7% | -$35.9M |
| CORT Corcept Therapeutics Incorporated | 75,274 | -44.9% | -$7.1M |
| DCTH Delcath Systems, Inc. | 604,664 | -30.6% | -$4.3M |
| CLDX Celldex Therapeutics, Inc. | 37,539 | -63.8% | -$2.1M |
| ACHV Achieve Life Sciences, Inc. | 3.86M | -4.2% | -$1.4M |
| KYTX Kyverna Therapeutics, Inc. | 700,595 | -20.7% | -$1.2M |
| FDMT 4D Molecular Therapeutics, Inc. | 179,154 | -29.1% | -$1.1M |
| IMUX Immunic, Inc. | 236,734 | -27.2% | -$821.1K |
| IVA Inventiva S.A. · ADR | 1.13M | -11.5% | -$543.4K |
| PALI Palisade Bio, Inc. | 2.22M | -13.9% | -$483.6K |
The 10 largest of each, by estimated dollars: shares changed times the later report's price. Index tracking, splits and mergers move positions too.
Compare two quarters
Pick any two quarters: what is new, added to, trimmed or exited. Premium plan.
Reported value by quarter
Value and number of positions at the end of each quarter.
Loading…
Largest positions in earlier quarters
Pick a quarter to see what the fund's biggest positions were then.
Loading…
Ten largest positions
By value, Q3 2026.
Filings
| Filing | ||||||
|---|---|---|---|---|---|---|
| Q3 2026 | Nov 13, 2026 | 13F-HR | 30 | $188.6M | Current | SEC ↗ |
| Q2 2026 | Aug 13, 2026 | 13F-HR | 29 | $191.1M | Current | SEC ↗ |
| Q1 2026 | May 14, 2026 | 13F-HR | 38 | $158.7M | Current | SEC ↗ |
| Q4 2025 | Feb 11, 2026 | 13F-HR | 20 | $117.1M | Current | SEC ↗ |
| Q3 2025 | Nov 12, 2025 | 13F-HR | 16 | $99.9M | Current | SEC ↗ |
| Q2 2025 | Aug 13, 2025 | 13F-HR | 16 | $82.4M | Current | SEC ↗ |
| Q1 2025 | May 15, 2025 | 13F-HR | 18 | $86.1M | Current | SEC ↗ |
Most recent first, up to 80. An amendment can replace a report or add holdings to it. All 13F filings
Information, not investment advice. Values are the fund's own figures at quarter end; a report can be up to 45 days old when filed. Disclaimer